隐源性肝硬化的临床流行病学及病理学特征

韩瑞; 张缭云

doi:10.3969/j.issn.1001-5256.2022.07.036

隐源性肝硬化的临床流行病学及病理学特征

DOI: 10.3969/j.issn.1001-5256.2022.07.036

韩瑞,
张缭云^, ,

山西医科大学第一医院感染病科，太原 030001

基金项目:

山西省科技厅重点研发计划项目 (201903D421056)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：韩瑞负责文献查找，资料分析，撰写论文; 张缭云负责拟定写作思路，指导撰写文章，修改论文并最后定稿。

详细信息

通信作者:
张缭云，zlysgzy@163.com

计量
- 文章访问数: 971
- HTML全文浏览量: 176
- PDF下载量: 97
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-27
- 录用日期: 2022-03-28
- 出版日期: 2022-07-20

Clinical epidemiology and pathological features of cryptogenic cirrhosis

Rui HAN,
Liaoyun ZHANG^{,
,}

Department of Infectious Diseases, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Key R & D Projects of Department of Science and Technology of Shanxi Province (201903D421056)

More Information

Corresponding author: ZHANG Liaoyun, zlysgzy@163.com(ORCID: 0000-0002-7666-7368)

摘要

摘要: 隐源性肝硬化，又称不明原因肝硬化，是指部分患者难以用目前已知的病因解释的肝硬化，临床上约占所有肝硬化的5%~10%。本文就隐源性肝硬化的病因、临床特点、结局等临床流行病学特点及其病理学特征的研究进展进行综述，旨在扩展临床诊治思维、帮助临床诊断。
- 隐源性肝硬化 /
- 流行病学 /
- 病理学，临床
Abstract: Cryptogenic cirrhosis (CC), also known as "unexplained liver cirrhosis", refers to liver cirrhosis in some patients that cannot be explained with known causes, and CC accounts for about 5%-10% of all liver cirrhosis cases in clinical practice. This article reviews the research advances in the clinical epidemiology of CC, including etiology, clinical features, outcome, and pathological features, in order to expand the thinking of clinical diagnosis and treatment and help with clinical diagnosis.
- Cryptogenic Cirrhosis /
- Epidemiology /
- Pathology, Clinical

HTML全文

参考文献(41)

[1]	KANG JH, MATSUI T. Changing etiology in liver cirrhosis in Sapporo, Japan[J]. Euroasian J Hepatogastroenterol, 2018, 8(1): 77-80. DOI: 10.5005/jp-journals-10018-1266.
[2]	SHAN S, ZHAO LH, MA H, et al. Definition, etiology, and epidemiology of liver cirrhosis[J]. J Clin Hepatol, 2021, 37(1): 14-16. DOI: 10.3969/j.issn.1001-5256.2021.01.003. 单姗, 赵连晖, 马红, 等. 肝硬化的定义、病因及流行病学[J]. 临床肝胆病杂志, 2021, 37(1): 14-16. DOI: 10.3969/j.issn.1001-5256.2021.01.003.
[3]	WANG XZ, LIU XF. Etiology and complications of liver cirrhosis: an clinical analysis of 2041 cases[J]. Zhejiang Med J, 2017, 39(1): 37-39. DOI: 10.12056/j.issn.1006-2785.2017.39.01.2016-1510. 王秀珍, 刘雪峰. 2041例肝硬化病因及并发症分析[J]. 浙江医学, 2017, 39(1): 37-39. DOI: 10.12056/j.issn.1006-2785.2017.39.01.2016-1510.
[4]	XU ZJ, ZHONG Y, LIU J, et al. Analysis of the characteristics of 58 cases of cryptogenic liver cirrhosis in Shanghai[J]. J Clin Hepatol, 2010, 26(3): 264-266. DOI: 10.3969/j.issn.1001-5256.2010.03.014. 徐正婕, 钟妍, 刘娇, 等. 上海地区58例隐源性肝硬化特点分析[J]. 临床肝胆病杂志, 2010, 26(3): 264-266. DOI: 10.3969/j.issn.1001-5256.2010.03.014.
[5]	RINALDI L, NASCIMBENI F, GIORDANO M, et al. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis[J]. World J Gastroenterol, 2017, 23(8): 1458-1468. DOI: 10.3748/wjg.v23.i8.1458.
[6]	YOUNOSSI ZM, BLISSETT D, BLISSETT R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J]. Hepatology, 2016, 64(5): 1577-1586. DOI: 10.1002/hep.28785.
[7]	SETIAWAN VW, STRAM DO, PORCEL J, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort[J]. Hepatology, 2016, 64(6): 1969-1977. DOI: 10.1002/hep.28677.
[8]	YANG YF. Imaging and pathological diagnosis of cirrhosis with unknown pathogen[J]. Chin J Pract Intern Med, 2019, 39(6): 501-505. DOI: 10.19538/j.nk2019060105. 杨永峰. 不明原因肝硬化的影像和病理学诊断[J]. 中国实用内科杂志, 2019, 39(6): 501-505. DOI: 10.19538/j.nk2019060105.
[9]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[10]	CZAJA AJ. Cryptogenic chronic hepatitis and its changing guise in adults[J]. Dig Dis Sci, 2011, 56(12): 3421-3438. DOI: 10.1007/s10620-011-1769-9.
[11]	CLARK JM, DIEHL AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis[J]. JAMA, 2003, 289(22): 3000-3004. DOI: 10.1001/jama.289.22.3000.
[12]	MOHAMMED OK, MAHADEVA S. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study[J]. J Gastroenterol Hepatol, 2015, 30(9): 1423-1428. DOI: 10.1111/jgh.12978.
[13]	O'LEARY JG, LANDAVERDE C, JENNINGS L, et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants[J]. Clin Gastroenterol Hepatol, 2011, 9(8): 700-704. e1. DOI: 10.1016/j.cgh.2011.04.007.
[14]	POONAWALA A, NAIR SP, THULUVATH PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study[J]. Hepatology, 2000, 32(4 Pt 1): 689-692. DOI: 10.1053/jhep.2000.17894.
[15]	TELLEZ-AVILA FI, SANCHEZ-AVILA F, GARCÍA-SAENZ-DE-SICILIA M, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis[J]. World J Gastroenterol, 2008, 14(30): 4771-4775. DOI: 10.3748/wjg.14.4771.
[16]	THULUVATH PJ, KANTSEVOY S, THULUVATH AJ, et al. Is cryptogenic cirrhosis different from NASH cirrhosis?[J]. J Hepatol, 2018, 68(3): 519-525. DOI: 10.1016/j.jhep.2017.11.018.
[17]	CARROZZO R, HIRANO M, FROMENTY B, et al. Multiple mtDNA deletions features in autosomal dominant and recessive diseases suggest distinct pathogeneses[J]. Neurology, 1998, 50(1): 99-106. DOI: 10.1212/wnl.50.1.99.
[18]	TWEEZER-ZAKS N, DORON-LIBNER A, WEISS P, et al. Familial Mediterranean fever and cryptogenic cirrhosis[J]. Medicine (Baltimore), 2007, 86(6): 355-362. DOI: 10.1097/MD.0b013e31815be056.
[19]	CHOWDHARY VR, CROWSON CS, POTERUCHA JJ, et al. Liver involvement in systemic lupus erythematosus: case review of 40 patients[J]. J Rheumatol, 2008, 35(11): 2159-2164. DOI: 10.3899/jrheum.080336.
[20]	IANNELLO S, BOSCO P, CAMUTO M, et al. A mild form of Alstrom disease associated with metabolic syndrome and very high fasting serum free fatty acids: two cases diagnosed in adult age[J]. Am J Med Sci, 2004, 327(5): 284-288. DOI: 10.1097/00000441-200405000-00031.
[21]	BADANO JL, MITSUMA N, BEALES PL, et al. The ciliopathies: an emerging class of human genetic disorders[J]. Annu Rev Genomics Hum Genet, 2006, 7: 125-148. DOI: 10.1146/annurev.genom.7.080505.115610.
[22]	BAY L, CANERO VELASCO C, CIOCCA M, et al. Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update[J]. Arch Argent Pediatr, 2017, 115(3): 287-293. DOI: 10.5546/aap.2017.eng.287.
[23]	DEHGHANI SM, IMANIEH MH, HAGHIGHAT M, et al. Etiology and complications of liver cirrhosis in children: report of a single center from southern iran[J]. Middle East J Dig Dis, 2013, 5(1): 41-46.
[24]	PINTO RB, SCHNEIDER AC, da SILVEIRA TR. Cirrhosis in children and adolescents: An overview[J]. World J Hepatol, 2015, 7(3): 392-405. DOI: 10.4254/wjh.v7.i3.392.
[25]	MAJUMDAR K, SAKHUJA P, PURI AS, et al. Coeliac disease and the liver: spectrum of liver histology, serology and treatment response at a tertiary referral centre[J]. J Clin Pathol, 2018, 71(5): 412-419. DOI: 10.1136/jclinpath-2017-204647.
[26]	JOSHI A, FALODIA S, KUMAR N, et al. Prevalence of celiac disease among pediatric patients with cryptogenic cirrhosis and effect of gluten-free-diet[J]. Indian J Gastroenterol, 2018, 37(3): 243-247. DOI: 10.1007/s12664-018-0857-6.
[27]	MOROTTI RA, SUCHY FJ, MAGID MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings[J]. Semin Liver Dis, 2011, 31(1): 3-10. DOI: 10.1055/s-0031-1272831.
[28]	BYRON D, MINUK GY. Clinical hepatology: profile of an urban, hospital-based practice[J]. Hepatology, 1996, 24(4): 813-815. DOI: 10.1002/hep.510240410.
[29]	GREEVE M, FERRELL L, KIM M, et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes[J]. Hepatology, 1993, 17(4): 593-598. DOI: 10.1002/hep.1840170411.
[30]	BELLE SH, BERINGER KC, DETRE KM. An update on liver transplantation in the United States: recipient characteristics and outcome[J]. Clin Transpl, 1995: 19-33.
[31]	SOOKOIAN S, PIROLA CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review[J]. J Hepatol, 2008, 49(4): 600-607. DOI: 10.1016/j.jhep.2008.06.012.
[32]	WONG RJ, AGUILAR M, CHEUNG R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States[J]. Gastroenterology, 2015, 148(3): 547-555. DOI: 10.1053/j.gastro.2014.11.039.
[33]	GOLABI P, BUSH H, STEPANOVA M, et al. Liver Transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the scientific registry of transplant recipients (SRTR): 1994 to 2016[J]. Medicine (Baltimore), 2018, 97(31): e11518. DOI: 10.1097/MD.0000000000011518.
[34]	YOUNOSSI Z, STEPANOVA M, SANYAL AJ, et al. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options[J]. J Hepatol, 2018, 69(6): 1365-1370. DOI: 10.1016/j.jhep.2018.08.013.
[35]	AYATA G, GORDON FD, LEWIS WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation[J]. Hum Pathol, 2002, 33(11): 1098-1104. DOI: 10.1053/hupa.2002.129419.
[36]	ARGO CK, NORTHUP PG, AL-OSAIMI AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis[J]. J Hepatol, 2009, 51(2): 371-379. DOI: 10.1016/j.jhep.2009.03.019.
[37]	CALDWELL SH, LEE VD, KLEINER DE, et al. NASH and cryptogenic cirrhosis: a histological analysis[J]. Ann Hepatol, 2009, 8(4): 346-352. DOI: 10.1016/S1665-2681(19)31748-X
[38]	POWELL EE, COOKSLEY WG, HANSON R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years[J]. Hepatology, 1990, 11(1): 74-80. DOI: 10.1002/hep.1840110114.
[39]	ABDELMALEK M, LUDWIG J, LINDOR KD. Two cases from the spectrum of nonalcoholic steatohepatitis[J]. J Clin Gastroenterol, 1995, 20(2): 127-130. DOI: 10.1097/00004836-199503000-00011.
[40]	NALBANTOGLU I, JAIN D. Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine[J]. Semin Diagn Pathol, 2019, 36(6): 389-394. DOI: 10.1053/j.semdp.2019.07.003.
[41]	CALDWELL SH, OELSNER DH, IEZZONI JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease[J]. Hepatology, 1999, 29(3): 664-669. DOI: 10.1002/hep.510290347.